Insomnia Treatment: CBT-I, Medication, and Safer Choices

Chronic insomnia treatment starts by confirming what is happening and what may be contributing to it. For most adults with chronic insomnia disorder, multicomponent cognitive behavioral therapy for insomnia, or CBT-I, is first-line care. Medication can be reasonable for selected people when benefits, risks, the specific sleep complaint, other health conditions, and patient preferences have been considered ¹².

This is not a choice between "therapy or nothing." CBT-I, a shorter behavioral program, medication, or a combination may each have a role. The right starting point depends on whether the problem is truly chronic insomnia, whether another disorder needs treatment, and what can be used safely.

First confirm the sleep problem

Chronic insomnia disorder involves difficulty falling asleep, staying asleep, or waking earlier than intended despite adequate opportunity and circumstances for sleep. It also causes meaningful distress or daytime impairment, occurs at least three nights per week, and has lasted at least three months ¹.

Symptoms lasting less than three months may be short-term insomnia. They still deserve attention when severe, but they do not automatically need the same long-term plan. A recent loss, illness, pain flare, new baby, schedule change, or medication may be the immediate driver ¹.

Insomnia is also different from simply not allowing enough time to sleep. If work, caregiving, social activity, or a deliberately short sleep window is the main reason for too little sleep, treatment starts by creating enough sleep opportunity.

A useful assessment asks:

• Is the main problem falling asleep, repeated or long awakenings, or waking too early, and how does it affect the next day?
• Is there enough time and a suitable setting for sleep?
• Does sleep become easier on a preferred schedule, suggesting a circadian rhythm sleep disorder rather than insomnia alone?
• Are there signs of sleep apnea, such as loud snoring, witnessed pauses, gasping, or marked daytime sleepiness?
• Is there an urge to move the legs that is worse at rest and relieved by movement, suggesting restless legs syndrome?
• Could pain, reflux, breathing symptoms, hot flashes, pregnancy, depression, anxiety, trauma symptoms, substance use, caffeine, alcohol, or a medicine be contributing?
• Is the person exhausted and unable to sleep, or sleeping very little without feeling a need for sleep? The second pattern, especially with an unusually high or irritable mood, racing thoughts, or risky behavior, can signal mania rather than ordinary insomnia ³.

A sleep diary and clinical history are often more useful for insomnia than a single night of testing. A sleep study is not required to diagnose chronic insomnia, but testing may be needed when symptoms suggest sleep apnea, a movement disorder, unusual sleep behaviors, or another sleep disorder ⁴. The focused insomnia diagnosis guide explains that process in more detail.

Treating a contributor does not always make established insomnia disappear. Pain, depression, anxiety, menopause symptoms, or sleep apnea may need treatment alongside insomnia rather than in a strict sequence. Evidence reviewed by the VA and DoD supports CBT-I in adults with several coexisting mental health conditions and in adults with comorbid pain, although the plan may need adaptation ¹.

CBT-I is the first-line treatment for chronic insomnia

CBT-I is not general talk therapy and it is not a list of sleep tips. It is a structured treatment that changes the behaviors, timing, and thought patterns that keep insomnia going. The AASM gives multicomponent CBT-I a strong recommendation, and the 2025 VA/DoD guideline recommends it over medication as first-line treatment ²¹.

A complete CBT-I program usually combines the following components ²¹:

• Stimulus control: strengthening the link between bed and sleep, while weakening the link between bed and prolonged wakefulness, frustration, or activity.
• Sleep restriction or sleep compression: temporarily matching time in bed more closely to sleep time, then adjusting it as sleep becomes more consolidated.
• Cognitive work: identifying rigid or frightening beliefs about sleep and replacing them with more accurate, useful responses.
• Arousal reduction: using relaxation or other strategies to reduce physical and mental activation around bedtime.
• Sleep education and targeted habit changes: addressing schedule, caffeine, alcohol, light, noise, and other factors that apply to the individual.

The name "sleep restriction" can be misleading. The aim is to reduce prolonged awake time in bed, not to leave someone chronically sleep deprived. Temporary sleepiness can occur early in treatment, so the schedule needs monitoring and adjustment ¹.

Sleep hygiene is support, not the treatment

A regular schedule, less late caffeine, a workable bedroom, and a wind-down routine may support sleep. They often do not undo the learned wakefulness, irregular time in bed, sleep effort, and fear that maintain chronic insomnia.

Both AASM and VA/DoD guidance advise against using sleep hygiene education as the only treatment for chronic insomnia. It can remain part of CBT-I, but handing someone a tip sheet is not equivalent to providing CBT-I ²¹.

CBT-I can be delivered in several formats

CBT-I may be provided individually, in a group, by telehealth or telephone, or through guided and unguided digital or self-help programs. Evidence reviewed in the VA/DoD guideline found improvements in insomnia severity and sleep efficiency across several formats. Therapist-delivered and guided formats have the most consistent support across outcomes and follow-up, but a credible digital program can be a useful access route when trained care is not available ¹.

Brief behavioral treatment for insomnia, or BBT-I, condenses the main behavioral components. It has a smaller evidence base than full CBT-I but is a guideline-supported option when a full program is not available ¹.

The CBT-I guide explains the full program. The focused guides on sleep restriction therapy and stimulus control explain those components without turning this treatment map into a do-it-yourself protocol.

When medication may fit

Needing medication does not mean CBT-I failed, and medication is not automatically required. It may be considered when CBT-I is unavailable, unacceptable, or insufficient; when symptoms are severe enough that temporary additional relief matters; or when a person makes an informed choice after discussing alternatives.

The 2026 AASM combination guideline found that starting CBT-I with medication was conditionally favored over medication alone, but not over CBT-I alone. The certainty was low, and most evidence covered short-term outcomes. This supports keeping CBT-I in the plan when medication is used rather than assuming the prescription replaces it ⁴.

Before prescribing, the clinician should define:

• the symptom being targeted;
• the expected benefit and how it will be measured;
• conditions or medicines that change the risk;
• how much sleep time will be available after taking it;
• what next-day activities require full alertness;
• when benefit, side effects, continued need, and the stopping plan will be reviewed.

No medication category is best for everyone. Recommendations are generally conditional or weak because average benefits are limited, trials are often short, and direct comparisons are scarce ⁵¹.

Medication category	Adult sleep complaint studied	Main selection boundaries
Dual orexin receptor antagonists	Difficulty falling asleep, staying asleep, or both, depending on the agent	Trials support improvements in some sleep outcomes, but the category is not a ranking of agents. Next-day sleepiness, interactions, breathing status, and other sleep disorders still matter 1.
Low-dose doxepin	Staying asleep or waking too early	Evidence is stronger for sleep maintenance than sleep onset. The low-dose insomnia use should not be treated as interchangeable with higher antidepressant doses 51.
Nonbenzodiazepine benzodiazepine receptor agonists, often called Z-drugs	Sleep onset, maintenance, or both, depending on the agent and formulation	Benefits must be weighed against next-day impairment, falls, and rare complex sleep behaviors. Eszopiclone, zaleplon, and zolpidem carry an FDA boxed warning for serious injury or death from activities performed while not fully awake 56.
Ramelteon	Difficulty falling asleep	AASM conditionally supported it for sleep onset in 2017, while the 2025 VA/DoD panel found insufficient evidence to recommend for or against it. This is a shared-decision option, not a universal next step 51.
Benzodiazepines	Sleep onset or maintenance, depending on the drug	Older trials led to conditional AASM recommendations for selected agents, but the 2025 VA/DoD guideline suggests against benzodiazepines for chronic insomnia because of the benefit-risk balance. Dependence, withdrawal, falls, interactions, and respiratory depression are central concerns 517.

This table describes how categories enter a clinical discussion. It does not provide doses, rank products, or replace the prescribing information. The sleep medication comparison covers agent-level differences, while the safe medication guide focuses on day-to-day precautions.

Sedation does not prove that a medicine treats chronic insomnia well

Diphenhydramine and doxylamine can make people drowsy, but first-generation antihistamines have weak evidence for chronic insomnia and can cause next-day impairment and anticholinergic effects. Tolerance to the sedating effect can also develop. The 2025 VA/DoD guideline suggests against diphenhydramine as chronic insomnia treatment ¹⁸.

Trazodone and antipsychotic medicines are also sedating, but that does not establish a favorable benefit-risk balance for chronic insomnia. The VA/DoD guideline suggests against trazodone and antipsychotics for this purpose ¹. This does not mean someone taking one of these medicines for depression, bipolar disorder, psychosis, or another condition should stop it. The indication and stopping plan belong with the prescriber.

Medication safety changes the decision

All insomnia medicines can impair driving and other alertness-dependent activities the next morning, sometimes even when the person feels awake. The risk depends on the medicine, formulation, dose, timing, metabolism, other substances, and available sleep time ⁹.

Eszopiclone, zaleplon, and zolpidem can rarely cause sleepwalking, sleep driving, cooking, or other activities while not fully awake, with serious injuries and deaths reported. FDA says these medicines should not be prescribed again to someone who previously had one of these complex sleep behaviors with them ⁶.

Benzodiazepines can cause physical dependence even when taken as prescribed. Abrupt discontinuation or a rapid dose reduction can cause severe and sometimes life-threatening withdrawal, including seizures. Combining a benzodiazepine with opioids, alcohol, or other central nervous system depressants increases the risk of profound sedation, respiratory depression, overdose, and death ⁷. Do not borrow a sedative, combine sleep medicines on your own, or stop a regularly used benzodiazepine abruptly.

For older adults, the medication review deserves extra weight. The 2023 American Geriatrics Society Beers Criteria advises avoiding benzodiazepines, Z-drugs, and first-generation antihistamines in most older adults because of risks that include cognitive impairment, delirium, falls, fractures, and motor vehicle crashes. It also notes that the sleep improvement from Z-drugs is small ⁸. This is a reason for an individualized review, not for suddenly stopping an existing medicine.

Breathing disorders, severe daytime sleepiness, a history of falls, cognitive impairment, pregnancy, substance use, liver or kidney disease, and other sedating medicines can all change the safest choice. A medication review should include over-the-counter products, cannabis, supplements, alcohol, and as-needed medicines, not only the prescription labeled for sleep ¹.

OTC products and supplements are not automatically safer

Melatonin is a circadian signal, not a general sedative that reliably treats every form of insomnia. It can be useful for selected circadian problems, but both the 2017 AASM guideline and the 2025 VA/DoD guideline suggest against it for chronic insomnia in adults because the reviewed evidence did not show a meaningful, consistent benefit ⁵¹. The melatonin guide explains how the purpose and timing differ by condition.

The same VA/DoD guideline suggests against valerian and cannabis or its derivatives for chronic insomnia. Cannabis studies were small, used different products, and produced mixed results. Valerian evidence was inconsistent and imprecise. The guideline found insufficient evidence to recommend for or against magnesium ¹. See the focused guides on valerian and cannabis for sleep for the formulation-specific evidence and safety questions.

"Natural" does not establish effectiveness, purity, interaction safety, or suitability during pregnancy or with another medicine. A supplement can also delay CBT-I or assessment of apnea, restless legs, pain, or a mood disorder ¹. Tell the clinician and pharmacist what you take, including teas, gummies, tinctures, and combination nighttime products.

Some people need an adapted plan

Older adults

CBT-I remains effective in older adults and avoids many medication risks. Review nighttime falls, bathroom trips, cognitive changes, other sedating or anticholinergic medicines, and untreated sleep apnea before narrowing time in bed or adding a sleep medicine ¹⁸. The older adults and insomnia guide covers those tradeoffs.

Pregnancy and postpartum

Pregnancy and the postpartum period can change both the sleep problem and which treatments are practical. The VA/DoD guideline lists pregnancy and postpartum insomnia among the situations that require CBT-I adaptation and tells clinicians to review reproductive status before medication ¹. Use an obstetric clinician and an insomnia clinician to build the plan rather than starting a sedative or supplement independently. See the postpartum insomnia guide for that specific setting.

Children and adolescents

The medication and CBT-I guidelines summarized here were written for adults. A child or teenager needs an age-appropriate assessment of schedule, development, mental health, breathing, movement symptoms, medicines, and family routines. Do not transfer an adult sleep-restriction schedule or medication plan to a child.

Bipolar disorder, seizures, and acute mental health symptoms

Sleep restriction can temporarily increase sleepiness and reduce sleep time early in treatment. The VA/DoD guideline advises adapting CBT-I for bipolar disorder and delaying or modifying it for uncontrolled seizure disorder, acute mental health symptoms, and some other high-risk situations ¹. This does not rule out CBT-I. It means the schedule should be clinician-guided and coordinated with the treatment of the other condition.

How to tell whether treatment is working

The goal is not a perfect score from a watch or never waking during the night. A useful treatment response includes less distress about sleep, shorter or fewer prolonged awakenings, a more dependable sleep window, and better daytime function.

Track the problem that treatment was chosen to address. A simple sleep diary can record bedtime, estimated sleep onset, awakenings, final wake time, time out of bed, naps, medication use, and daytime sleepiness. Review the pattern rather than reacting to one night.

If a reasonable treatment trial is not helping, reassess before adding remedies. The diagnosis may be incomplete, a contributor may be untreated, the CBT-I plan may need adjustment, the medication may target the wrong symptom, or side effects may outweigh a small benefit. Referral to a behavioral sleep medicine or sleep medicine clinician is appropriate when the diagnosis is unclear, CBT-I needs adaptation, or symptoms persist despite treatment ¹.

Seek prompt or urgent help if:

• sleepiness makes driving, caregiving, or safety-critical work unsafe ⁹;
• a Z-drug causes sleepwalking, sleep driving, or another complex behavior while the person is not fully awake ⁶;
• a sedating medicine causes severe confusion, a fall, or an injury;
• someone is hard to wake or has slow or difficult breathing after a benzodiazepine is combined with an opioid, alcohol, or another depressant ⁷;
• reducing or missing a regularly used benzodiazepine is followed by severe shaking, hallucinations, confusion, or a seizure ⁷;
• little or no sleep occurs with a markedly high, wired, or irritable mood, racing thoughts, risky behavior, hallucinations, or delusions ³;
• insomnia occurs with suicidal thoughts or an inability to stay safe.

Effective insomnia care is usually a sequence of clear decisions: identify the sleep pattern, treat relevant contributors, use CBT-I as the foundation, and add medication only when its specific benefit is worth its specific risk.